Coupled with the recent announcement that they will be doing clinical studies on one of their products to gauge its impact for pre-diabetic individuals, All American Pharmaceutical & Natural Food Corporation (AAP) also received approval on a grant application to reduce costs for expansion, by the board of the Big Sky Economic Development Authority (EDA). AAP plans to invest $650,000 in new equipment and staffing at their location at 2375 Main Street.
As a contract manufacturer of dietary supplements, AAP is researching the impact their product, KarboLyn®, has on glucose response in normal, and pre-diabetic adults during aerobic activity.
The clinical study will be headed by Dr. Thomas Harman, a former Family Medicine Department chairman at the Mayo Clinic in Rochester, Minnesota.
AAP has applied for a $180,000 grant from Big Sky Economic Development Trust Fund, Category 1 Grant.